Please assess the completion status of the following clinical trial:

Trial Title: GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects achieving clinical response (CDAI decrease of at least 100 points) and/or remission (CDAI less than 150) upon completion of treatment in Study CCX114151 or another GSK sponsored induction study~* Written informed consent prior to any CCX114157 specific study procedures~* Females of child-bearing potential must be sexually inactive or commit to use of consistent and correct use of contraceptive methods with a failure rate of less than 1 percent~* Stable doses of Crohn's disease medications~* Subjects on corticosteroids at entry must be willing to undergo corticosteroid dose taper during the study~Exclusion Criteria:~* If female, is pregnant, has a positive pregnancy test or is breast-feeding~* Subjects with known or suspected coeliac disease or a positive screening test (anti-tissue transglutaminase antibodies) should have been excluded from enrolment into the induction studies. Subjects in whom a diagnosis of coeliac disease is subsequently suspected should have this excluded with testing for anti-tissue transglutaminase antibodies prior to enrolment into the maintenance study.~* Known or suspected fixed symptomatic small bowel stricture~* Enterocutaneous, abdominal or pelvic fistulae likely to require surgery during the study period~* Current sepsis or infections requiring intravenous antibiotic therapy for greater than 2 weeks~* Evidence of hepatic dysfunction, viral hepatitis, or liver function abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- GSK1605786A once daily (Type: EXPERIMENTAL): 500 milligrams once daily
- GSK1605786A twice daily (Type: EXPERIMENTAL): 500 milligrams twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).